AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
Study NCT00126984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
Study NCT03551665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective step training
Description: Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
Study NCT03256435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAMP PrEP initiation, adherence, and retention intervention
Description: The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
Study NCT03661086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
Study NCT03400813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-TEP EMDR
Description: Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
Study NCT00279812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50ug selenium enriched yeast
Description: Selenomethionine supplement (50ug/d Se) for 12 weeks
Study NCT00279812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100ug selenium enriched yeast
Description: Selenomethionine supplement (100ug/d Se) for 12 weeks
Study NCT00279812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200ug selenium enriched yeast
Description: Selenomethionine supplement (200ug/d Se) for 12 weeks
Study NCT00279812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control onion
Description: 3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
Study NCT00279812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched onion
Description: 3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
Study NCT00279812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement for 12 weeks
Study NCT04313491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early cessation of steroids
Description: Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids
Study NCT01729494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: early cessation of steroids
Description: Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids
Study NCT00007644 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate
Study NCT02438345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCr5
Study NCT02438345 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCr5
Study NCT02631265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 1
Description: Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
Study NCT02631265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 2
Description: Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
Study NCT02631265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 3
Description: Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
Study NCT03477058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 3308 cosmetic product for topical use
Description: Application on the entire body at least once a day over two weeks
Study NCT03684694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion.
Study NCT03684694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral capsule.
Study NCT02291926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
Study NCT03826823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSG cannula
Description: a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
Study NCT04340804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kcal labelling
Description: Real-time kcal counter synchronised with the food amount changes
Study NCT04340804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE labelling
Description: Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
Study NCT02469662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexel Total Elbow
Description: Nexel Total Elbow used in primary or revision total elbow arthroplasty
Study NCT02589873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Diabetes Prevention Program
Description: Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
Study NCT02589873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Diabetes Prevention Program
Description: Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
Study NCT02694562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40um Embozene TANDEM Microspheres
Description: 40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
Study NCT02023892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Study NCT04303780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 21 day cycles
Study NCT03259386 — intervention group
Intervention type: DEVICE
Intervention: Microelectrode array
Description: Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
Study NCT00200044 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gatekeeper Reflux Repair System
Description: The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
Study NCT00200044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gatekeeper Reflux Repair System
Description: The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
Study NCT00141778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once a day
Study NCT02023892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04050267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
Study NCT04050267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - air
Description: Breathing air with 21 % oxygen, no nitrous oxide.
Study NCT00387647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine given subcutaneously as outlined in treatment arm.
Study NCT04030247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant Sterol
Description: Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
Study NCT02408809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Smoking Cessation Discussion
Description: This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
Study NCT02176850 — intervention group
Intervention type: DRUG
Intervention: Micardis®
Study NCT04408482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation
Description: Cannulation of biliary duct by sphincterotome
Study NCT02408809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic Related Smoking Cessation Discussion
Description: The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
Study NCT00892359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
Study NCT04039412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid regimen
Description: two-step (dual-quadruple) treatment
Study NCT04039412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reverse hybrid regimen
Description: one-step two-phase (quadruple-dual) treatment
Study NCT04039412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin quadruple regimen
Description: non-Clarithromycin non-Bismuth quadruple therapy
Study NCT01330485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation Training
Description: The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
Study NCT01330485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common Factor Control Condition
Description: The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
Study NCT00999557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution
Description: Applied topically
Study NCT05053841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00999557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study NCT02197806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
Study NCT02197806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
Study NCT02197806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Study NCT00141778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Taken orally, once a day
Study NCT00141778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Taken orally, once a day
Study NCT03338725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy model
Description: Patients who are being monitored by a clinical pharmacy model
Study NCT03338725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pharmacy model
Description: Patients who are being monitored by a clinical pharmacy model
Study NCT03423940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional communication training
Description: During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior).
Study NCT02629666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERS and/or Self-management Strategies
Study NCT03601559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei Lpc-37
Description: Live probiotic bacteria
Study NCT03601559 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo matched for taste and appearance
Study NCT02210832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practices
Study NCT02558205 — intervention group
Intervention type: RADIATION
Intervention: CT Liver Perfusion
Description: Imaging study of liver using injection of Iodine contrast agent done using CT imaging
Study NCT02558205 — intervention group
Intervention type: RADIATION
Intervention: PET/CT of liver
Description: PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.